Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK increases stake in Indian Pharmaceuticals subsidiary to 75 per cent after Open Offer
GlaxoSmithKline plc announced today that, following the voluntary Open Offer undertaken by its subsidiary, GlaxoSmithKline Pte Ltd, it has successfully increased its stake in it...
Read more -
GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia
GlaxoSmithKline plc (LSE:GSK) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promacta™ (eltrombo...
Read more -
GSK kicks off 2014 Discovery Fast Track Challenge for academic drug hunters in Europe, Canada and USA
GSK is inviting academic scientists to enter their most innovative drug research proposals into its 2014 Discovery Fast Track Challenge.
Read more -
Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use...
Read more -
GSK receives positive CHMP opinion for Incruse® (umeclidinium) for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinio...
Read more -
GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis
GSK today announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist.
Read more -
Results announcement for fourth quarter 2013
GSK announces core EPS of 112.2p and dividend of 78p.
Read more -
GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia
GlaxoSmithKline plc (LSE:GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag).
Read more -
GSK announces headline results for Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) in metastatic melanoma
GlaxoSmithKline plc [LSE/NYSE: GSK] today announced that a Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib), compared to single agent ther...
Read more -
GSK receives positive opinion from the CHMP in Europe for once-weekly EperzanTM (albiglutide) for the treatment of type 2 diabetes
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive o...
Read more -
ViiV Healthcare’s new HIV medicine TivicayTM (dolutegravir) is approved in Europe
ViiV Healthcare today announced that the European Commission has approved TivicayTM (dolutegravir).
Read more -
Prosensa regains rights to drisapersen from GSK and retains rights to all other programmes for the treatment of Duchenne muscular dystrophy (DMD)
Prosensa Holding N.V. (NASDAQ: RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to drisapersen.
Read more -
Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Tafinlar® (dabrafenib).
Read more -
GSK gains accelerated FDA approval for combination use of Mekinist® (trametinib) and Tafinlar® (dabrafenib)
GlaxoSmithKline plc [LSE/NYSE: GSK ] announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (...
Read more -
GSK adds detailed clinical trial data to multi-sponsor request system as part of continued commitment to data transparency
GlaxoSmithKline (GSK) has added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system.
Read more -
GSK completes divestment of thrombosis brands and related manufacturing site to Aspen
GlaxoSmithKline (GSK) today completed the previously announced divestment of its thrombosis brands, ArixtraTM and FraxiparineTM.
Read more -
GSK completes divestment of Lucozade and Ribena to Suntory
GlaxoSmithKline (GSK) today completed the previously announced divestment of its nutritional drinks brands Lucozade and Ribena.
Read more -
GSK Cervarix® two-dose schedule receives European marketing authorisation
GSK announced today that the European Commission has granted marketing authorisation for its cervical cancer vaccine Cervarix.
Read more -
GSK and MMV announce FDA Breakthrough Therapy designation for tafenoquine for Plasmodium vivax malaria
GSK and Medicines for Malaria Venture (MMV) announced today that the FDA has granted Breakthrough Therapy designation for tafenoquine.
Read more -
Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR®
Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR®
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
